TOPIC: 2021 American Transplant Congress

Characterization of Chronic Renal Allograft Dysfunction at Single Cell Resolution
C. Kuscu¹, C. Kuscu², A. Shetty³, M. Talwar⁴, J. Eason², D. G. Maluf⁵, V. Mas⁶
Characterization of Kidney Small Extracellular Vesicles Released During Normothermic Machine Perfusion
W. W. Woud¹, A. Arykbaeva², D. de Vries², I. Alwayn², K. Boer¹, C. Baan¹, M. Hoogduijn¹, R. Minnee³
Characterization of Retransplantation Following Graft Failure Due to Bkvn
K. Nguyen¹, H. Curtis², J. Panichella², H. Resweber³, A. Di Carlo², S. Karhadkar¹
Characterization of SGLT2 Inhibitor Use After Abdominal Transplant
F. Hailemariam¹, S. Yeager², J. Schulte³, P. Singh¹, A. Yadav¹
Characterizing Kidney Transplant Recipients with SARS-CoV-2: An Academic Single Center Experience
S. Nahi, A. Shetty, S. Tanna, J. Leventhal
Characterizing the Early Impact of the Kidney Accelerated Placement Project on Hard-to-place Kidneys
J. D. Motter, A. Kernodle, M. Levan, D. Segev, J. Garonzik-Wang, A. Massie
CHBP Induces Stronger Immunosuppressive CD127⁺ M-MDSC via Erythropoietin Receptor
C. Yang
Classification of Distinct Patterns of Ischemic Cholangiopathy Following DCD Liver Transplantation: Distinct Clinical Courses and Long-Term Outcomes from a Multicenter Cohort
K. P. Croome¹, A. K. Mathur², B. Aqel², L. Yang¹, J. K. Heimbach³, T. Taner³, C. B. Rosen³, R. Paz-Fumagalli¹, C. Taner¹
Clazakizumab (clz, Anti-il-6 Antibody) Treatment Affects Il-6/il-6r Signaling by Increasing Soluble Gp130 (sgp130) in Hla-sensitized Kidney Transplant Patients (hs Ktx Pts) Treated for Chronic Antibody-mediated Rejection (cabmr)
B. Shin, S. Ge, A. Jimenez, N. Ammerman, A. Vo, R. Zhang, S. C. Jordan, M. Toyoda
Clazakizumab for the Treatment of Chronic Active Antibody-Mediated Rejection in Kidney Transplant Recipients: Phase 3 IMAGINE Study Design
P. Nickerson¹, G. Böhmig², S. Chadban³, D. Kumar⁴, R. B. Mannon⁵, T. van Gelder⁶, S. Adler⁷, E. Chong⁷, A. Djamali⁸